title: Roles of group II metabotropic glutamate receptors in modulation of seizure activity.
abstract: Evidence suggests that metabotropic glutamate receptors (mGluR) are involved in mediating seizures and epileptogenesis. In the present experiments, the selective, group II mGluR agonist (+)-2-aminobicyclo-[3.1.0]hexane-2,6-dicarboxylic acid (LY354740, 0.1-1.0 microM) inhibited spontaneous epileptiform discharges which developed in rat cortical slices in Mg2+-free medium. LY354740 (4-16 mg/kg) administered prior to an injection of pentylenetetrazol (80 mg/kg) or picrotoxin (3.2 mg/kg) produced a dose-dependent decrease in the number of mice exhibiting clonic convulsions, but had no effect on N-methyl-D-aspartate (NMDA, 150 mg/kg)-induced convulsions. LY354740 (4-16 mg/kg) did not affect lethality induced in mice by pentylenetetrazol, picrotoxin or NMDA. LY354740 potentiated the anticonvulsant activity of the conventional antiepileptic drug diazepam, significantly decreasing the ED50 for that drug's effect on pentylenetetrazol-induced convulsions by 30%, but had no influence on anticonvulsant activity of ethosuximide and valproic acid. A pharmacokinetic interaction between LY354740 and diazepam, leading to the lowering of the plasma level of free diazepam, was also demonstrated. Our data suggest that the group II mGluR agonist LY354740 possesses anti-seizure activity and may modify the effects of some conventional antiepileptic drugs.
authors.affiliation: Institute of Pharmacology, Polish Academy of Sciences, Krakow.
authors.forename: A
authors.initials: A
authors.lastname: Kłodzińska
authors.forename: M
authors.initials: M
authors.lastname: Bijak
authors.forename: E
authors.initials: E
authors.lastname: Chojnacka-Wójcik
authors.forename: B
authors.initials: B
authors.lastname: Kroczka
authors.forename: M
authors.initials: M
authors.lastname: Swiader
authors.forename: S J
authors.initials: SJ
authors.lastname: Czuczwar
authors.forename: A
authors.initials: A
authors.lastname: Pilc
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000502:physiology; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D003292:Convulsants / Q000037:antagonists & inhibitors* / Q000633:toxicity; D003975:Diazepam / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004594:Electrophysiology; D008297:Male; D051379:Mice; D016202:N-Methylaspartate; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors*; D010852:Picrotoxin / Q000037:antagonists & inhibitors*; D051381:Rats; D017208:Rats, Wistar; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists*; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D014151:Anti-Anxiety Agents; D001643:Bridged Bicyclo Compounds; D003292:Convulsants; D003975:Diazepam; D004338:Drug Combinations; D016202:N-Methylaspartate; D010433:Pentylenetetrazole; D010852:Picrotoxin; D018094:Receptors, Metabotropic Glutamate; C104753:eglumetad